ArticleCureus2025
Embryonal Rhabdomyosarcoma of the Uterine Cervix in a Patient With Xeroderma Pigmentosum: An Exceptional Association.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical rhabdomyosarcoma (RMS) is an uncommon malignant tumor. Its presentation in patients with xeroderma pigmentosum (XP), a genetic condition with marked ultraviolet (UV) sensitivity and skin cancer risk, is very rare. We report the case of a teenage girl with XP diagnosed with embryonal rhabdomyosarcoma of the uterine cervix. A 17-year-old girl with a longstanding history of XP presented with pelvic pain, abnormal vaginal bleeding, dysuria, and constipation. Clinical examination revealed a 7 × 6 cm exophytic cervical mass. Histopathological analysis confirmed the diagnosis of embryonal rhabdomyosarcoma of the cervix. Management included neoadjuvant chemotherapy based on the IVA protocol (ifosfamide, vincristine, and actinomycin D), followed by total hysterectomy and bilateral pelvic lymphadenectomy. The patient is currently undergoing adjuvant chemotherapy, with no clinical or radiological evidence of recurrence. This exceptional association between XP and cervical embryonal rhabdomyosarcoma presents complex diagnostic and therapeutic challenges. It underscores the importance of multidisciplinary management and heightened vigilance for rare tumors in the context of XP. Further research is warranted to better understand the management of extracutaneous malignancies in patients with XP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.